1. Amidon, G. L., & Löbenberg, R. (2000). Modern bioavailability bioequivalence, and biopharmaceutics classification system - new scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 3–12.
2. Martinez, M., Augsburger, L., Johnston, T., & Jones, W. (2002). Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Biopharmaceutics and formulation considerations. Advanced Drug Delivery Reviews, 54(6), 805–824.
3. Kolli, C. S., Gannu, R., Yamsani, V. V., Kishan, V., & Yamsani, M. R. (2008). Development of mucoadhesive patches for buccal administration of prochlorperazine: evaluation of in vitro release and mechanical properties. International Journal of Pharmaceutical Sciences and Technology, 1(1), 64–70.
4. Badshah, A., Subhan, F., Shah, N. H., Bukhari, N. I., Saeed, M., & Shah, K. U. (2012). Once daily controlled release matrix tablet of Prochlorperazine maleate: influence of Ethocel and/or Methocel on in vitro drug release and bioavailability. Drug Development and Industrial Pharmacy, 38(2), 190–199.
5. Isah, A. O., Rawlins, M. D., & Bateman, D. N. (1991). Clinical pharmacology of prochlorperazine in healthy young males. British Journal of Clinical Pharmacology, 32(6), 677–684.